Zobrazeno 61 - 70
of 275
pro vyhledávání: ''
Autor:
Mikkael A. Sekeres, Matt Kalaycio, Hien K. Duong, Alan E. Lichtin, Ramon V. Tiu, H. J. Rogers, Li Zhang, Daniel J. Lindner, Yvonne Parker, Gustavo A. Heresi, Valeria Visconte, Ali Tabarroki, Stavros E. Mountantonakis
Publikováno v:
Leukemia. 28:1486-1493
Pulmonary hypertension (PH) is a frequently under recognized complication of myelofibrosis (MF). The pathophysiology of PH in MF is unknown and no definitive therapies have been established. We studied 15 patients with MF-associated PH and compared t
Autor:
Aleksandr Suvorov, Goranova-Marinova, Sanjay K. Aggarwal, Gianluca Gaidano, Douglas E. Joshua, Nehal Mohamed, W. J. Chng, H. Goldschmidt, Meletios A. Dimopoulos, Albert Oriol, Thierry Facon, Heinz Ludwig, Laura Rosiñol, Katja Weisel, Heidi H. Gillenwater, Shibao Feng, Philippe Moreau, Luděk Pour, Roman Hájek, Tomas Pika, Ruben Niesvizky, Antonio Palumbo
Publikováno v:
Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refract
Autor:
Shaji Kumar, Arleigh McCurdy, Suzanne R. Hayman, John A. Lust, Shivlal Pandey, S V Rajkumar, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Stephen J. Russell, Angela Dispenzieri, Steven R. Zeldenrust, Robert A. Kyle, David Dingli, Prashant Kapoor, Nelson Leung
Publikováno v:
Leukemia
Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patient
Autor:
KC Anderson, Sagar Lonial
Publikováno v:
Leukemia
Since the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, more patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer. T
Autor:
Richard J. Jones, Jing Yang, Hua Wang, Heather Lin, Donna M. Weber, Jatin J. Shah, Veerabhadran Baladandayuthapani, Isere Kuiatse, Robert Z. Orlowski, Sheeba K. Thomas, Chad C. Bjorklund, Michael Wang
Publikováno v:
Leukemia. 28:373-383
Resistance of myeloma to lenalidomide is an emerging clinical problem, and though it has been associated in part with activation of Wnt/β-catenin signaling, the mediators of this phenotype remained undefined. Lenalidomide-resistant models were found
Autor:
Andreas Hochhaus, Francis J. Giles, Frank Hong, P. le Coutre, Michael J. Mauro, Giuseppe Saglio, Richard C. Woodman, Christine-Elke Ortmann, C. McNeill
Publikováno v:
Leukemia. 27:1310-1315
Peripheral arterial occlusive disease (PAOD) occurs in patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs). The risk of developing PAOD on TKI therapy is unknown and causality has not been esta
Autor:
Alvin F. Wong, Zhengping Wang, Thomas Martin, Jeffrey A. Zonder, Susan Lee, Ashraf Badros, Ravi Vij, Lori Kunkel, Ruben Niesvizky
Publikováno v:
Leukemia
This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodia
Autor:
Cristina Correia, Scott H. Kaufmann, Kevin L. Peterson, Paula A. Schneider, Brian D. Koh, Grzegorz S. Nowakowski, Husheng Ding
Publikováno v:
Leukemia
Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we
Autor:
Richard Houghton, V Iglesias, S. Stilgenbauer, John G. Gribben, Michael Hallek, Günter Fingerle-Rowson, Mark Dixon, Ciara L. Freeman, Valentin Goede, C S de Costa, K-A Kreuzer, Marco Herling, S Böttcher, Kathryn Humphrey
Publikováno v:
Leukemia
Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
Autor:
Ezhilarasi Chendamarai, Ansu Abu Alex, Christine Chomienne, Raja C. Mugasimangalam, Saravanan Ganesan, A. Srivastava, Poonkuzhali Balasubramanian, Nithya Balasundaram, Ajay Abraham, Uday Kulkarni, Hamenth Kumar Palani, Sachin David, Mohammed Aiyaz, Biju George, Vikram Mathews, Rose Ann Padua, Anu Korula
Publikováno v:
Leukemia
Arsenic trioxide (ATO) mediates PML-RARA (promyelocytic leukemia–retinoic acid receptor-α) oncoprotein degradation via the proteasome pathway and this degradation appears to be critical for achieving cure in acute promyeloytic leukemia (APL). We h